Skip to main content

Table 4 Sensitivity and specificity of potential diagnostic biomarkers in pancreatic cancer

From: Evaluation of serum ATX and LPA as potential diagnostic biomarkers in patients with pancreatic cancer

Biomarkers

Optimum cut-off

Sensitivity (%)

Specifificity (%)

PC vs. Controls

   

 CA19-9

≥ 57 U/mL

80.21

75

 ATX

≥ 286 ng/mL

78.95

80

 LPA

≥ 10.7 µg/mL

91.74

69.4

TS1 + TS2 vs. Controls

   

 CA19-9

≥ 57 U/mL

77.33

75

 ATX

≥ 286 ng/mL

65.33

80

 LPA

≥ 10.7 µg/mL

80.67

69.4

TS3 + TS4 vs. Controls

   

 CA19-9

≥ 57 U/mL

82.26

75

 ATX

≥ 286 ng/mL

89.6

80

 LPA

≥ 10.7 µg/mL

95.65

69.4

  1. Controls: healthy volunteers + benign pancreatic diseases
  2. TS, tumor stage